IMRT Usage and Cost Related to Geography And Medicare Reimbursement Policy, Study Finds
Aflibercept Improves Overall Survival In Second-Line Colorectal Cancer Setting
Motesanib Does Not Improve OS; Study Doesn’t Meet Primary Endpoint
Beta Blockers Negate Harmful Recurrence Risks of ACE Inhibitors
Study Validates “PEM” Scans As Biopsy Guidance Method
Prostatectomy Lowers Death Risk Compared to Watchful Waiting
Postponed Surgery For Low-Grade Prostate Cancer Adds No Risk
Acupuncture Can Relieve Side Effects of Hormone Treatment
Selumetinib Displays Positive Results, 60% with Stable Disease
National Health Organizations Warn of Risks in Indoor Tanning
Clinical Trials Approved By NCI CTEP Last Month
SWOG Launching New Study Based on Recurrence Test Scores
Centocor Withdraws Yondelis After FDA Calls for New Study
FDA Approves New Device For Glioblastoma Multiforme
EU Gives Marketing Approval For HBV Sequencing Test
Roche Markets CMV Test in Europe
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- What happened at FDA? Replimune approval raises questions
- I grew up unhoused. Now, with support from ACS, I am an MD-PhD student focused on oncology
My mother instilled in me: “Never become a product of your circumstances.” - Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial
